Advanced search
Publication Cover
Current Medical Research and Opinion Volume 37, 2021 - Issue 6
Submit an article Journal homepage
1,955
Views
5
CrossRef citations to date
0
Altmetric
Pain Medicine

Lasmiditan efficacy in migraine attacks with mild vs. moderate or severe pain

Mario F. P. Peresa Neurology, Hospital Israelita Albert Einstein, São Paulo, Brazil;b Instituto de Psiquiatria, Hospital das Clínicas da Faculdade de Medicina, São Paulo, BrazilORCID Iconhttps://orcid.org/0000-0002-0068-1905
ORCID Icon,
Raghavendra Vasudevac Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USACorrespondence[email protected]
,
Simin K. Bayganic Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
,
Ellen B. Dennehyc Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA;d Psychological Sciences, Purdue University, West Lafayette, IN, USA
,
Maurice Vincentc Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USAORCID Iconhttps://orcid.org/0000-0001-5855-6069
ORCID Icon &
Deborah I. Friedmane Neurology and Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX, USA
Pages 1031-1038 | Received 14 Dec 2020, Accepted 11 Mar 2021, Published online: 07 Apr 2021

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Christopher C Anderson & Juliana H VanderPluym. (2023) Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy. Drug Design, Development and Therapy 17, pages 1979-1993.
Read now

Articles from other publishers (4)

Messoud Ashina, Caroline Roos, Lily Qian Li, Mika Komori, David Ayer, Dustin Ruff & John Henry Krege. (2023) Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial. Cephalalgia 43:4, pages 033310242311617.
Crossref
Olivia Begasse de Dhaem, Tsubasa Takizawa & David W Dodick. (2023) Long-term open-label and real-world studies of lasmiditan, ubrogepant, and rimegepant for the acute treatment of migraine attacks. Cephalalgia 43:2, pages 033310242211370.
Crossref
Alicia Alpuente, Victor J Gallardo, Edoardo Caronna, Marta Torres-Ferrus & Patricia Pozo-Rosich. (2021) In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study. The Journal of Headache and Pain 22:1.
Crossref
Richard B. Lipton, Simin K. Baygani, Stewart J. Tepper, John H. Krege, Raghavendra Vasudeva, Eric M. Pearlman, Paula M. Hauck & Li Shen Loo. (2021) A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN. The Journal of Headache and Pain 22:1.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.